The treatment of malignancies in HIV patients is challenged by the issue of drug–drug interactions between antiretroviral therapy and antineoplastic agents. While protease inhibitors have been shown to increase the incidence and severity of cancer therapy-related side effects, the impact of other antiretroviral agents on the tolerability and response to chemotherapy is less well documented. We report the successful use of an etravirine-based regimen in a patient treated with BEACOPP chemotherapy for advanced Hodgkin’s lymphoma. Etravirine constitutes a valuable option for concomitant use with chemotherapy due to its moderate inducing effect on drug metabolising enzymes.
SimcockMBlaskoMKarrerU. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther2007; 12: 931–939.
2.
CoronaGVaccherESpinaM. Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin’s lymphoma. AIDS2013; 27: 1033–1039.
3.
CingolaniATortiLPinnettiC. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin’s lymphoma. AIDS2010; 24: 2408–2411.
4.
KakudaTNvan Solingen-RisteaRMOnkelinxJ. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy volunteers. J Clin Pharmacol2014; 54: 422–431.
5.
AntoniouTTsengAL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet2005; 44: 111–145.
6.
DennisonJBKulanthaivelPBarbuchRJ. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos2006; 34: 1317–1327.
7.
DennisonJBJonesDRRenbargerJL. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther2007; 321: 553–563.
8.
ZembruskiNCHaefeliWEWeissJ. Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother2011; 55: 1282–1284.
9.
GranforsMTWangJSKajosaariLI. Differential inhibition of cytochrome P450 3A4, 3A5, and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol2006; 98: 79–85.
